AcquisitionOther
BioCryst Pharmaceuticals, Inc. acquired Astria Therapeutics, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
BioCryst Pharmaceuticals, Inc. -> Astria Therapeutics, Inc. · $700 million
To strengthen position as a leader in hereditary angioedema and enhance long-term growth trajectory with late-stage navenibart therapy.
Open source record (SEC) ↗